Cargando…

Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge

The purpose of this study was to evaluate the efficacy of a new, single-dose bivalent vaccine containing porcine circovirus type 2b (PCV2b) and Mycoplasma hyopneumoniae against a dual PCV2b and M. hyopneumoniae challenge. At −25 days post challenge (dpc, 10 days of age), one pig group (designated as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Yongjun, Yang, Siyeon, Oh, Taehwan, Park, Kee Hwan, Cho, Hyejean, Suh, Jeongmin, Chae, Chanhee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119751/
https://www.ncbi.nlm.nih.gov/pubmed/33996979
http://dx.doi.org/10.3389/fvets.2021.652313
_version_ 1783691920010117120
author Ahn, Yongjun
Yang, Siyeon
Oh, Taehwan
Park, Kee Hwan
Cho, Hyejean
Suh, Jeongmin
Chae, Chanhee
author_facet Ahn, Yongjun
Yang, Siyeon
Oh, Taehwan
Park, Kee Hwan
Cho, Hyejean
Suh, Jeongmin
Chae, Chanhee
author_sort Ahn, Yongjun
collection PubMed
description The purpose of this study was to evaluate the efficacy of a new, single-dose bivalent vaccine containing porcine circovirus type 2b (PCV2b) and Mycoplasma hyopneumoniae against a dual PCV2b and M. hyopneumoniae challenge. At −25 days post challenge (dpc, 10 days of age), one pig group (designated as the vaccinated/challenged group) received a single, 1.0 ml dose of bivalent vaccine. Pigs in both the vaccinated/challenged and unvaccinated/challenged groups were then inoculated intranasally with PCV2b and M. hyopneumoniae at 0 dpc (35 days of age). Pigs in vaccinated/challenged group induced significantly higher levels of neutralizing antibodies against PCV2b and cell-mediated immunity against PCV2b and M. hyopneumonia when compared with pigs in unvaccinated/challenged group. The vaccination of pigs with a bivalent vaccine also reduced PCV2b viremia, reduced mycoplasmal nasal shedding, and decreased the severity of both lung and lymphoid lesions for PCV2b and M. hyopneumoniae infection, respectively. The results of this study demonstrated that the evaluated bivalent vaccine was effective in protecting pigs against PCV2b and M. hyopneumoniae infection.
format Online
Article
Text
id pubmed-8119751
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81197512021-05-15 Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge Ahn, Yongjun Yang, Siyeon Oh, Taehwan Park, Kee Hwan Cho, Hyejean Suh, Jeongmin Chae, Chanhee Front Vet Sci Veterinary Science The purpose of this study was to evaluate the efficacy of a new, single-dose bivalent vaccine containing porcine circovirus type 2b (PCV2b) and Mycoplasma hyopneumoniae against a dual PCV2b and M. hyopneumoniae challenge. At −25 days post challenge (dpc, 10 days of age), one pig group (designated as the vaccinated/challenged group) received a single, 1.0 ml dose of bivalent vaccine. Pigs in both the vaccinated/challenged and unvaccinated/challenged groups were then inoculated intranasally with PCV2b and M. hyopneumoniae at 0 dpc (35 days of age). Pigs in vaccinated/challenged group induced significantly higher levels of neutralizing antibodies against PCV2b and cell-mediated immunity against PCV2b and M. hyopneumonia when compared with pigs in unvaccinated/challenged group. The vaccination of pigs with a bivalent vaccine also reduced PCV2b viremia, reduced mycoplasmal nasal shedding, and decreased the severity of both lung and lymphoid lesions for PCV2b and M. hyopneumoniae infection, respectively. The results of this study demonstrated that the evaluated bivalent vaccine was effective in protecting pigs against PCV2b and M. hyopneumoniae infection. Frontiers Media S.A. 2021-04-30 /pmc/articles/PMC8119751/ /pubmed/33996979 http://dx.doi.org/10.3389/fvets.2021.652313 Text en Copyright © 2021 Ahn, Yang, Oh, Park, Cho, Suh and Chae. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Ahn, Yongjun
Yang, Siyeon
Oh, Taehwan
Park, Kee Hwan
Cho, Hyejean
Suh, Jeongmin
Chae, Chanhee
Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge
title Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge
title_full Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge
title_fullStr Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge
title_full_unstemmed Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge
title_short Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge
title_sort efficacy evaluation of a bivalent vaccine containing porcine circovirus type 2b and mycoplasma hyopneumoniae against an experimental dual challenge
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119751/
https://www.ncbi.nlm.nih.gov/pubmed/33996979
http://dx.doi.org/10.3389/fvets.2021.652313
work_keys_str_mv AT ahnyongjun efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge
AT yangsiyeon efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge
AT ohtaehwan efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge
AT parkkeehwan efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge
AT chohyejean efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge
AT suhjeongmin efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge
AT chaechanhee efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge